Rapid Biopharma Response To COVID-19 Enabled By Decades Of R&D Investment, Firms Say
Executive Summary
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
You may also be interested in...
Industry, Agencies Are Making COVID-19 Partnerships Easy
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
Pfizer, Fosun Partner BioNTech On mRNA COVID-19 Vaccine
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
COVID-19 Study Of Gilead’s Remdesivir Using Ebola-Style Adaptive Platform Trial
First COVID-19 experimental treatment trial in US is a master protocol that echoes NIH’s Ebola treatment approach.